Amendment No. 1 to Schedule 13D

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UlfK7ppI8ITA4J3vDXLESXqlPN8iUAB/CvztGnh9KACCr7kg7Y+Y37gv7UWElJTo rEKkVTeVJU7tpMzv/ViOpw== 0001193125-07-188928.txt : 20070824 0001193125-07-188928.hdr.sgml : 20070824 20070824152320 ACCESSION NUMBER: 0001193125-07-188928 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070824 DATE AS OF CHANGE: 20070824 GROUP MEMBERS: INVUS ADVISORS, L.L.C. GROUP MEMBERS: INVUS PUBLIC EQUITIES ADVISORS, LLC GROUP MEMBERS: INVUS PUBLIC EQUITIES, L.P. GROUP MEMBERS: RAYMOND DEBBANE GROUP MEMBERS: ULYS, L.L.C. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-60409 FILM NUMBER: 071078292 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Invus, L.P. CENTRAL INDEX KEY: 0001404570 IRS NUMBER: 830359143 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O THE INVUS GROUP, L.L.C. STREET 2: 750 LEXINGTON AVENUE, 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212 371 1717 MAIL ADDRESS: STREET 1: C/O THE INVUS GROUP, L.L.C. STREET 2: 750 LEXINGTON AVENUE, 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 SC 13D/A 1 dsc13da.htm AMENDMENT NO. 1 TO SCHEDULE 13D Amendment No. 1 to Schedule 13D

Schedule 13D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Lexicon Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

528872104

(CUSIP Number)

Raymond Debbane

c/o Ulys, L.L.C.

750 Lexington Avenue

30^th Floor

New York, New York 10022

(212) 371-1717

Copies to:

Robert Spatt, Esq.

Peter Malloy, Esq.

Simpson Thacher & Bartlett LLP

425 Lexington Avenue

New York, NY 10017

(212) 455-2000




		(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 23, 2007




		(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Schedule 13D

CUSIP No. 528872104


1.		Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Invus, L.P. I.R.S. Identification No. 83-0359143
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6.		Citizenship or Place of Organization Bermuda


Number of Shares Beneficially Owned by Each Reporting Person With		7. Sole Voting Power 50,824,986
		8. Shared Voting Power 0
		9. Sole Dispositive Power 50,824,986
		10. Shared Dispositive Power 0


11.		Aggregate Amount Beneficially Owned by Each Reporting Person 50,824,986
12.		Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13.		Percent of Class Represented by Amount in Row (11) 37.16%*
14.		Type of Reporting Person (See Instructions) PN

*	Based on 85,965,249 shares of Issuer Common Stock outstanding as of August 23, 2007, as provided by the Issuer, plus an estimated 50,824,986 shares expected to be issued to Invus, L.P. pursuant to a securities purchase agreement with the Issuer, as described below.

Schedule 13D

CUSIP No. 528872104


1.		Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Invus Advisors, L.L.C. I.R.S. Identification No. 83-0359142
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With		7. Sole Voting Power 50,824,986
		8. Shared Voting Power 0
		9. Sole Dispositive Power 50,824,986
		10. Shared Dispositive Power 0


11.		Aggregate Amount Beneficially Owned by Each Reporting Person 50,824,986
12.		Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13.		Percent of Class Represented by Amount in Row (11) 37.16%*
14.		Type of Reporting Person (See Instructions) OO

*	Based on 85,965,249 shares of Issuer Common Stock outstanding as of August 23, 2007, as provided by the Issuer, plus an estimated 50,824,986 shares expected to be issued to Invus, L.P. pursuant to a securities purchase agreement with the Issuer, as described below.

Schedule 13D

CUSIP No. 528872104


1.		Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Invus Public Equities, L.P. I.R.S. Identification No. 98-0420215
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6.		Citizenship or Place of Organization Bermuda


Number of Shares Beneficially Owned by Each Reporting Person With		7. Sole Voting Power 3,891,108
		8. Shared Voting Power 0
		9. Sole Dispositive Power 3,891,108
		10. Shared Dispositive Power 0


11.		Aggregate Amount Beneficially Owned by Each Reporting Person 3,891,108
12.		Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13.		Percent of Class Represented by Amount in Row (11) 4.53%*
14.		Type of Reporting Person (See Instructions) PN

*	Based on 85,965,249 shares of Issuer Common Stock outstanding as of August 23, 2007, as provided by the Issuer.

Schedule 13D

CUSIP No. 528872104


1.		Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Invus Public Equities Advisors, LLC I.R.S. Identification No. 98-04220201
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With		7. Sole Voting Power 3,891,108
		8. Shared Voting Power 0
		9. Sole Dispositive Power 3,891,108
		10. Shared Dispositive Power 0


11.		Aggregate Amount Beneficially Owned by Each Reporting Person 3,891,108
12.		Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13.		Percent of Class Represented by Amount in Row (11) 4.53%*
14.		Type of Reporting Person (See Instructions) OO

*	Based on 85,965,249 shares of Issuer Common Stock outstanding as of August 23, 2007, as provided by the Issuer.

Schedule 13D

CUSIP No. 528872104


1.		Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Ulys, L.L.C. I.R.S. Identification No. 83-0359139
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With		7. Sole Voting Power 54,716,094
		8. Shared Voting Power 0
		9. Sole Dispositive Power 54,716,094
		10. Shared Dispositive Power 0


11.		Aggregate Amount Beneficially Owned by Each Reporting Person 54,716,094
12.		Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13.		Percent of Class Represented by Amount in Row (11) 40.0%*
14.		Type of Reporting Person (See Instructions) OO

*	Based on 85,965,249 shares of Issuer Common Stock outstanding as of August 23, 2007, as provided by the Issuer, plus an estimated 50,824,986 shares expected to be issued to Invus, L.P. pursuant to a securities purchase agreement with the Issuer, as described below.

Schedule 13D

CUSIP No. 528872104


1.		Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Raymond Debbane
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6.		Citizenship or Place of Organization Panama


Number of Shares Beneficially Owned by Each Reporting Person With		7. Sole Voting Power 54,716,094
		8. Shared Voting Power 0
		9. Sole Dispositive Power 54,716,094
		10. Shared Dispositive Power 0


11.		Aggregate Amount Beneficially Owned by Each Reporting Person 54,716,094
12.		Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13.		Percent of Class Represented by Amount in Row (11) 40.0%*
14.		Type of Reporting Person (See Instructions) IN

*	Based on 85,965,249 shares of Issuer Common Stock outstanding as of August 23, 2007, as provided by the Issuer, plus an estimated 50,824,986 shares expected to be issued to Invus, L.P. pursuant to a securities purchase agreement with the Issuer, as described below.

Schedule 13D

This Amendment No. 1 hereby amends and supplements the statement of beneficial ownership on Schedule 13D, relating to the common stock, $0.001 par value per share (the “Issuer Common Stock”), of Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Issuer” or “Lexicon”), initially filed on June 27, 2007 (the “Statement”). All capitalized terms not otherwise defined herein have the meaning assigned to them in the Statement.

Item 3.

Source and Amount of Funds or Other Consideration

Item 3 of the Statement is hereby amended and supplemented by replacing the second paragraph thereof with the following:

The purchase of additional shares of Issuer Common Stock by Invus, L.P. up to an aggregate of approximately $205,472,250, as contemplated by the Securities Purchase Agreement (as defined below), was subject to stockholder approval, which was obtained on August 23, 2007. Invus, L.P. intends to use funds obtained from a capital call to its limited partners in respect of previously made commitments for the payment of the purchase price for any such additional shares of Issuer Common Stock.

Item 4.

Purpose of Transaction

Item 4 of the Statement is hereby amended and supplemented by inserting the following immediately after the first paragraph thereof:

On August 23, 2007, at the special meeting of stockholders of the Issuer, the Issuer’s stockholders voted to approve the transactions contemplated by the Securities Purchase Agreement, the Warrant Agreement, the Registration Rights Agreement and the Stockholders’ Agreement. At the special meeting, the Issuer’s stockholders also voted to approve an amendment to the Issuer’s certificate of incorporation to increase the number of authorized shares of common stock from 120 million to 300 million.

Pursuant to the Securities Purchase Agreement, at the closing of the Initial Investment, Lexicon will issue and sell to Invus, L.P. a number of shares of Issuer Common Stock that will result in Invus, L.P. owning 40% of the Issuer Common Stock outstanding on the date of such closing. Based on the number of shares of Issuer Common Stock outstanding as of August 23, 2007, the date of the special meeting of stockholders of the Issuer, the number of shares to be purchased by Invus, L.P. in the Initial Investment is estimated to be 50,824,986. The number of shares actually issued at the closing may deviate from this estimate based on changes in the number of outstanding shares of Issuer Common Stock between August 23, 2007, and the closing of the Initial Investment, which is expected to occur on August 28, 2007, subject to the satisfaction of the closing conditions contained in the Securities Purchase Agreement.

Item 5.

Interest in Securities of the Issuer

Item 5 of the Statement is hereby amended and supplemented by replacing the first, second and third paragraphs of clause (a) thereof with the following:

Schedule 13D

As of August 23, 2007, Invus Public Equities, L.P. was the record and beneficial owner of 3,891,108 shares of Issuer Common Stock, representing approximately 4.53% of the outstanding shares of Issuer Common Stock (not taking into account the shares of Issuer Common Stock issuable upon the exercise of the Warrants or to be issued to Invus, L.P. in the Initial Investment). Invus Public Equities Advisors, LLC, as the general partner of Invus Public Equities, L.P., controls Invus Public Equities, L.P. and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock held by Invus Public Equities, L.P. Invus Public Equities Advisors, LLC disclaims such beneficial ownership, except to the extent of its pecuniary interest in such shares.

As of August 23, 2007, Invus, L.P. may be deemed to beneficially own 50,824,986 shares of Issuer Common Stock estimated to be issued to it in the Initial Investment, representing approximately 37.16% of the outstanding shares of Issuer Common Stock (taking into account the shares of Issuer Common Stock to be issued to Invus, L.P. in the Initial Investment). This number does not include the 16,498,353 shares of Issuer Common Stock subject to the Warrants. Although the Warrants will remain outstanding and exercisable until the occurrence of the closing of the Initial Investment, purchases of shares of Issuer Common Stock upon the exercise of Warrants will reduce the number of shares to be purchased by Invus, L.P. in the Initial Investment and will not change the number of shares of Issuer Common Stock to be beneficially owned by Invus, L.P. as of the closing of the Initial Investment.

Invus Advisors, L.L.C., as the general partner of Invus, L.P., controls Invus, L.P. and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock held by Invus, L.P. Invus Advisors, L.L.C. disclaims such beneficial ownership, except to the extent of its pecuniary interest in such shares. Invus, L.P. has certain rights to acquire additional shares of Issuer Common Stock, as described in Item 6.

Ulys, L.L.C., as the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C., controls each of these two entities and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock held by them. Ulys, L.L.C. disclaims such beneficial ownership, except to the extent of its pecuniary interest in such shares. As the sole member of Ulys, L.L.C., Mr. Raymond Debbane controls Ulys, L.L.C. and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock held by Ulys, L.L.C. Mr. Raymond Debbane disclaims such beneficial ownership, except to the extent of his pecuniary interest in such shares.

Item 6.

Contracts, Arrangements or Understandings with Respect to Securities of the Issuer

Item 6 of the Statement is hereby amended and supplemented by adding the following at the end of the first paragraph under the heading “Securities Purchase Agreement—Stockholder Approval” in such Item:

Such stockholder approval was obtained on August 23, 2007.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


INVUS, L.P.
By: INVUS ADVISORS, L.L.C., its general partner

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

INVUS PUBLIC EQUITIES, L.P.
By: INVUS PUBLIC EQUITIES ADVISORS, LLC, its general partner

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

INVUS ADVISORS, L.L.C.

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

INVUS PUBLIC EQUITIES ADVISORS, LLC

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

ULYS, L.L.C.

By:		/s/ Raymond Debbane
Name:		Raymond Debbane
Title:		President

RAYMOND DEBBANE

/s/ Raymond Debbane

Dated: August 24, 2007

-----END PRIVACY-ENHANCED MESSAGE-----